Clinical and Translational Research
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2024; 12(18): 3505-3514
Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3505
Exploring the potential mechanism of WuFuYin against hypertrophic scar using network pharmacology and molecular docking
Shu-Yang Zhang, Song-Xue Guo, Lei-Lei Chen, Jia-Yan Zhu, Ming-Sheng Hou, Jia-Ke Lu, Xue-Xiang Shen
Shu-Yang Zhang, Jia-Yan Zhu, Xue-Xiang Shen, Department of General Surgery, Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing 312000, Zhejiang Province, China
Song-Xue Guo, Department of Plastic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China
Lei-Lei Chen, Hand and Plastic Surgery, The first People’s Hospital of Linping District, Hangzhou 311013, Zhejiang Province, China
Ming-Sheng Hou, Department of Pathology, Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing 312000, Zhejiang Province, China
Jia-Ke Lu, Department of Traumatology, Yuyao Hospital of Traditional Chinese Medicine, Ningbo 315400, Zhejiang Province, China
Author contributions: Zhang SY, Guo SX, and Chen LL contributed to the conception and design; Zhang SY, Zhu JY, and Hou MS contributed to the collection and assembly of data; Lu JK and Shen XX analyzed and interpreted the data; and all authors wrote and approved the final manuscript.
Supported by the 2022 Shaoxing City Health Science and Technology Program (Health Science and Technology Program), No. 2022KY050.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xue-Xiang Shen, MD, Associate Chief Physician, Department of General Surgery, Shaoxing Hospital of Traditional Chinese Medicine, No. 641 Renmin Middle Road, Yuecheng District, Shaoxing 312000, Zhejiang Province, China. zsyzsy0522@163.com
Received: March 1, 2024
Revised: April 23, 2024
Accepted: April 30, 2024
Published online: June 26, 2024
Processing time: 109 Days and 1.1 Hours
Core Tip

Core Tip: This study identified 8 hub genes [CKD2, ABCC1, MMP2, MMP9, glycogen synthase kinase 3 beta (GSK3B), PRARG, MMP3, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG)] and five key compounds (MOL004941, MOL004935, MOL004866, MOL004993, and MOL004989) in the WuFuYin (WFY) as an effective treatment for hypertrophic scar (HTS). We found that PI3K-Akt pathway played a crucial role in the WFY. The results of molecular docking showed that GSK3B and cyclin dependent kinase 2 affected HTS through targeting MOL004941, MOL004989, and MOL004993.